On 18 September, Timmins Gold Corp. (NYSEMKT:TGD) shares fell -0.66% and was closed at $0.23. TGD EPS growth in last 5 year was -51.01%. Timmins Gold Corp. (NYSEMKT:TGD) year to date (YTD) performance is -76.12%.
Timmins Gold has a proven track record of delivering growth and value creation for its investors and is poised to become an emerging intermediate, Mexican-focused gold producer with a portfolio of high-quality production and growth assets all based in Mexico.
On Sep 18, Timmins Gold Corp. (NYSEMKT:TGD) announce that it has entered into an agreement with a Mexican subsidiary of Goldcorp Inc. (“Goldcorp”) to acquire the complete process plant and select auxiliary equipment (“Plant”) used in the operation of Goldcorp’s El Sauzal Mine in Chihuahua, Mexico (“the Plant Acquisition”). The El Sauzal Mine was operational until December 2014 when it began its closure.
uniQure N.V. (NASDAQ:QURE) shares increased 6.06% in last trading session and ended the day at $33.41. QURE has a return on assets of -40.00%. uniQure N.V. (NASDAQ:QURE) quarterly performance is 6.37%.
uniQure N.V., a biopharmaceutical company, develops adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas.
uniQure N.V. (NASDAQ:QURE) announced the topline results of one-year follow-up data from a Phase I/II clinical trial conducted by Institut Pasteur (Biotherapies for Neurodegenerative Diseases Unit, Institut Pasteur/INSERM) in partnership with the French Muscular Dystrophy Association and Vaincre les Maladies Lysosomales (collectively “the consortium”) in four Sanfilippo B syndrome (MPSIIIB) patients treated with a novel gene therapy, AMT-110. In all four patients, researchers verified the restoration of catalytical activity of the NaGlu protein in the cerebrospinal fluid (CSF) from 0% at baseline up to 14-17% of normal at 3 months with persistent effect at 12 months.
Sandstorm Gold Ltd. (NYSEMKT:SAND) caters to the Basic Materials space. Its weekly performance is 11.76%. On the last day of trading company shares ended up at $2.85. Sandstorm Gold Ltd. (NYSEMKT:SAND) distance from 50-day simple moving average (SMA50) is 5.68%.
Sandstorm Gold Ltd. (NYSEMKT:SAND) is announcing, pursuant to National Instrument 62-103 – The Early Warning System and Related Take Over Bid and Insider Reporting Issues, the purchase by Sandstorm of an aggregate of 2,617,400 common shares (the “Acquired Shares”) of AuRico Metals Inc. (“AuRico”), representing approximately 2% of the outstanding common shares of AuRico (the “AuRico Shares”). Prior to the acquisition of the Acquired Shares, Sandstorm owned directly an aggregate of 16,791,881 AuRico Shares, which represents approximately 13% of the issued and outstanding AuRico Shares. Upon completion of the acquisition of the Acquired Shares, an aggregate 19,409,281 AuRico Shares are now owned directly by Sandstorm, representing approximately 15% of the issued and outstanding AuRico Shares.
Sandstorm Gold Ltd. is a gold streaming and royalty company. Sandstorm provides upfront financing to gold mining companies that are looking for capital and in return, receives the right to a percentage of the gold produced from a mine, for the life of the mine. Sandstorm has acquired a portfolio of 72 streams and royalties, of which 14 of the underlying mines are producing.
On 18 September, Cablevision Systems Corporation (NYSE:CVC) shares moved up 1.91% and was closed at $33.13. CVC EPS growth in last 5 year was 21.00%. Cablevision Systems Corporation (NYSE:CVC) year to date (YTD) performance is 64.01%.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cablevision Systems Corporation (NYSE:CVC) relating to the proposed buyout of the Company by Altice N.V.
Cablevision Systems Corporation, together with its subsidiaries, owns and operates cable systems in the United States. The company operates through three segments: Cable, Lightpath, and Other.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) shares moved up 7.95% in last trading session and ended the day at $2.24. CRBP has a return on assets of -84.10%. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) quarterly performance is -29.34%.
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate, Resunab™, is a novel synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation, bacterial infections, and fibrotic processes. Resunab is currently in Phase 2 studies for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis and skin-predominant dermatomyositis.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), announced that patient enrollment has commenced in the Phase 2 clinical study of its investigational new drug Resunab™ for the treatment of cystic fibrosis (“CF”). Resunab is a novel oral drug targeting the resolution of inflammation and fibrosis associated with disease progression in CF across all CFTR gene mutations. In a pre-clinical CF animal model, Resunab ameliorated inflammation, weight loss, bacterial infection and improved survival.
Leave a Reply